ABDALLAH ABTWALIBE MAGHEMBE

Mr. ABDALLAH ABTWALIBE MAGHEMBE

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2025 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
AMABDALLAH ABTWALIBE MAGHEMBE
ABDALLAH ABTWALIBE MAGHEMBE
MBMarion Sumari-De Boer
Marion Sumari-De Boer
MMMtoro Jabar Mtoro
Mtoro Jabar Mtoro
MMMichael Johnson Mahande
Michael Johnson Mahande
Antiretroviral therapy (ART) reduces morbidity and mortality due to human immunodeficiency virus (HIV) infection. In 2019, Tanzania adopted Dolutegravir (DTG) as a first-, second-line, and third-line treatment for children and adolescents living with HIV (CALHIV). Viral load suppression (VLS) is desirable in the prevention of HIV transmission thus achieving the third ‘95’ target. DTG treatment has highly potent antiviral activity, a high genetic barrier to resistance, and a high safety profile. We aimed to determine VLS and associated factors among CALHIV on DTG-based ART in Tanzania. We conducted a retrospective cohort analysis among CALHIV who were on a DTG-based regimen in Tanzania between 2019 and 2021. We extracted demographic and clinical characteristics from the care and treatment clinic database. A multilevel mixed effects Poisson regression model was used to determine factors associated with VLS at < 1000 copies/ml among CALHIV on a DTG-based regimen. A total of 63,453 CALHIV on a DTG-based regimen were analysed. The proportion of viral suppression was 91.64%. Overall, 66.19% of previously unsuppressed individuals became suppressed, and 88.45% of previously suppressed remained suppressed. Factors leading to higher chances of viral suppression were aged 15–19 years (aRR: 1.02; 95%CI: 1.017–1.03), those in WHO stage I (aRR: 1.03; 95%CI: 1.01–1.04), those in WHO stage II (aRR: 1.02; 95%CI: 1.00-1.04), and those who ever received a multi-month prescription on ART (aRR: 1.25; 95% CI: 1.23–1.28), while those aged 10–14 years (aRR: 0.98; 95%CI: 0.97–0.99), previously unsuppressed prior to starting DTG (aRR: 0.92; 95%CI: 0.91–0.93), duration on ART more than 24 months (aRR: 0.96; 95%CI: 0.94–0.97), not retained in care (aRR: 0.83; 95% CI: 0.77–0.89), severe malnutrition (aRR:0.77; 95%CI: 0.69–0.94) and coastal zone (aRR: 0.98; 95% CI: 0.96–0.99) were less likely to achieve VLS. This study showed DTG-based regimens have a good response for both naïve, previously unsuppressed, and suppressed Children and Adolescents Living with HIV (CALHIV) with significant improvement in viral suppression. Improving retention in care and malnutrition might improve VLS and achieve the third ‘95’.

25 May 2023 in medRxiv
Verified
Preprint
Open access
PDF file
AMABDALLAH ABTWALIBE MAGHEMBE
ABDALLAH ABTWALIBE MAGHEMBE
MBMarion Sumari-De Boer
Marion Sumari-De Boer
GMGodbless Marikias
Godbless Marikias
CACaroline Amour
Caroline Amour
MMMichael Johnson Mahande
Michael Johnson Mahande
Introduction: Antiretroviral therapy (ART) reduces morbidity and mortality due to human immunodeficiency virus (HIV) infection. The complexity and time-consuming processes, particularly in drug approvals, have contributed to a major challenge to the ongoing success of antiretroviral treatment programs among children and adolescents. In 2019, Tanzania adopted DTG as a first-, second-line and third-line treatment for CALHIV on ART after being approved by the World Health Organisation (WHO). DTG treatment has highly potent antiviral activity, a high genetic barrier to resistance, and a high safety profile. This study aimed to determine HIV viral suppression and associated factors among CALHIV on DTG-based ART in Tanzania Mainland. Methods: This was a retrospective cohort analysis among children and adolescents living with HIV who were on a DTG-based regimen in Tanzania Mainland between 2019 and 2021. The study utilized routinely collected data from Tanzania Care and Treatment Centres (CTC). We analysed data using STATA version 15 software. We calculated the prevalence of viral suppression by taking the number of children and adolescents with <1000 copies/ml overall study participants. A mixed effect generalized linear model with Poisson distribution and log link function with robust estimator determined the factors associated with HIV viral suppression on a DTG-based regimen. Results: A total of 63,453 CALHIV on a DTG-based regimen were analysed. The proportion of viral suppression was 91.64%. Overall, 66.19% of previously unsuppressed individuals became suppressed and 88.45% of previously suppressed remained suppressed. Factors leading to lower chances of viral suppression were age 10-14 years (aRR: 0.98; 95%CI: 0.97-0.99), previously unsuppressed prior to starting DTG (aRR: 0.92; 95%CI: 0.91-0.93), duration on ART more than 24 months (aRR: 0.96; 95%CI: 0.94-0.97), not retained in care (aRR: 0.83; 95% CI: 0.77-0.89), severe malnutrition (aRR:0.77; 95%CI: 0.69-0.94) and coastal zone (aRR: 0.98; 95% CI: 0.96-0.99), while those in WHO stage I (aRR: 1.03; 95%CI: 1.01-1.04) and ever received a multi-month prescription (aRR: 1.25; 95% CI: 1.23-1.28) had a higher chance of viral suppression. Conclusions: The findings support the broad use of DTG-based regimens for eligible CALHIV. Especially those in baseline WHO stage I and those who received the multi-month prescriptions were more likely to achieve viral load suppression. Programs should improve strategies to maintain CALHIV retention in care with interventions like the promotion of teen clubs and teams.

16 June 2026 in BMJ Open
Verified
Journal Article
Open access
EMElvis Bazil Meela
Elvis Bazil Meela
GWGilbert Waria
Gilbert Waria
LSLaura J Shirima
Laura J Shirima
HMHenry Lucas Mlay
Henry Lucas Mlay
MNMichael Ngowi
Michael Ngowi
JNJames Samwel Ngocho
James Samwel Ngocho
Objectives: To examine trends and factors associated with isoniazid preventive therapy (IPT) initiation among people living with HIV (PLHIV) aged ≥15 years who initiated antiretroviral therapy (ART) in mainland Tanzania between 2015 and 2020. Design: A retrospective observational study using routinely collected data. Multilevel logistic regression analysis was used to identify factors associated with IPT initiation. Setting: HIV care and treatment clinics across mainland Tanzania. Participants: The study included PLHIV aged ≥15 years who initiated ART between 2015 and 2020. Primary and secondary outcome measures: The primary outcome was IPT initiation among eligible PLHIV. Secondary outcomes included trends in IPT initiation from 2015 to 2020 and factors associated with IPT initiation. Results: Among 124 846 PLHIV (mean age 35.8±11.40 years), cumulative IPT initiation was 59.8% (10.50% at first visit; 21.70% within 3 months). Initiation trend increased from 52.70% in 2015 to 68.30% in 2020 (2.05, p<0.02). Factors positively associated with IPT initiation included female sex (adjusted OR (aOR) 1.10, 95% CI 1.10 to 1.20), (aOR, CI) working functional status compare to bedridden (aOR 1.90, 95% CI 1.50 to 2.50), care at a health centre versus dispensary (aOR 1.60, 95% CI 1.30 to 2.00), residence in the Lake zone versus Central zone (aOR 2.50, 95% CI 1.60 to 3.80), ART initiation in 2020 compare to 2015 (aOR 2.00, 95% CI 1.90 to 2.20), WHO HIV stage II versus stage IV (aOR 2.10, 95% CI 1.90 to 2.30) and age 45–54 years compare to 15–24 years (aOR 1.90, 95% CI 1.80 to 2.10). Conclusion: Although IPT initiation among PLHIV in mainland Tanzania improved between 2015 and 2020, coverage remained suboptimal. Strengthened efforts are needed to ensure all PLHIV initiating ART are appropriately screened for tuberculosis (TB), initiated on IPT if eligible and promptly treated if diagnosed with active TB.